Moderna secures $750 mln from Blackstone Life Sciences to develop flu shots
Moderna said on Wednesday Blackstone’s life sciences arm would offer $750 million in funding towards its flu vaccines, bolstering its efforts to advance multiple vaccines to stem a post-COVID slump in sales.